Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (July 2020)
17 slides from Genetic Signatures's investor presentation, Jul 28, 2020
Slide 1: Investor presentation
Investor presentation 28 July 2020
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is propr
Slide 3: A global leader in the supply of molecular diagnostic solutions
A global leader in the supply of molecular diagnostic solutions A specialist molecular diagnostics company Share price (A$) Volume (m) 2.8 3.0 Focused on becoming a global leader in the 2.4 2.5 supply of molecular diagnostic solutions 2.0 2.0 Developing and commercialising its proprietary 1.6 platfo
Slide 4: Investment highlights
Investment highlights Significant opportunity Trusted and proven Competitive advantage created by COVID-19 technology Rapid development of the 100% customer retention since 2016 Underpinned by novel 3baseTM EasyScreenTM SARS-CoV-2 and the accuracy of the technology technology providing increas
Slide 5: Trusted and proven technology: EasyScreen products built on 3base technology
Trusted and proven technology: EasyScreenTM products built on 3baseTM technology Our Products Transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays. Our automated sample preparation method is suitable for bacterial, p
Slide 6: Competitive advantage: 3base technology creates potential benefits for multiple key stakeholders
Competitive advantage: Genetic Signatures’ 3baseTM technology creates potential benefits for multiple key stakeholders qPCR1 detection methodology used, the gold standard for infectious disease diagnosis Rapid time to results, with results processed from 4 hours, for up to 188 specimens Screen
Slide 7: Significant product and market expansion plans
Significant product and market expansion plans: underpins long-term business growth and shareholder value EasyScreenTM products Asia Pacific EMEA Americas Global market size1 (TGA) (CE-IVD) (FDA) ( A$ per annum) Protozoan Clinical trials Enteric Viral delayed due to $573m COVID-19 Bacterial
Slide 8: FY20 milestones
FY20 milestones: Genetic Signatures has made significant operational progress in FY20, reflected by positive share price performance Share Price (A$) +114% share price over LTM 2.50 April 2020: CE-IVD received for October 2019: SARS-CoV-2 kit 2.00 $35m Placement to accelerate global March 2020: expa
Slide 9: Significant revenue growth
Significant revenue growth: continued to achieve strong year-on-year revenue growth and a milestone quarter in 4Q FY2020 Revenue (A$m) Exceptional year for Genetic Signatures +131% 11.3 Unaudited revenue for FY20 of $11.3m, a +131% on pcp Record quarterly revenue in 4Q FY20 of $7.0m, a +351% on
Slide 10: Growth underpinned by scalable revenue model: attractive unit economics
Growth underpinned by scalable revenue model: attractive unit economics Attractive revenue model Contributing to attractive economics High throughput with predictable orders – Target customers are high throughput pathology groups, hospitals or government run programs 100% customer retention since
Slide 11: COVID-19 global pandemic: burden on testing expected to increase
COVID-19 global pandemic: as countries move towards re-opening, the burden on testing is expected to significantly increase 2 EMEA: • ~300k people have tested positive to COVID-19 in the UK4 • 320k people were tested for COVID-19 between 2 July and 8 July contributing to a total of 13.6m tests condu
Slide 12: On track to achieve multiple commercial milestones
On track to achieve multiple commercial milestones: multiple upcoming milestones in FY21 that could accelerate revenue growth • CE-IVD received allowing marketing of the kit in Europe with orders received Near term opportunities for • TGA registration received allowing marketing of the kit in Austra
Slide 13: Appendices
Genetic Signatures Transforming Molecular Diagnostics Appendices
Slide 14: Novel proprietary technology: 3base platform underpins the EasyScreen product range
Novel proprietary technology: proprietary 3baseTM platform technology underpins the EasyScreenTM product range Our proprietary 3baseTM solution… …improves workflow and increases throughput 1 3baseTM platform technology converts original EasyScreen™ kits are compatible with 4-base microbial genome to
Slide 15: Board of Directors: proven track records of commercialisation success
Board of Directors: proven track records of commercialisation success across key geographic regions • Significant experience in leading international sales expansions of biotech companies Nick Samaras • Former Managing Director of Applied Biosystems (acquired by ThermoFisher, US$76.8bn market Non-Ex
Slide 16: International management team
International management team: highly skilled researchers and executives bring a broad array of experience and knowledge • One of the pioneers of the bisulphite genomic sequencing protocol with a PhD in Molecular Genetics Dr. Doug Millar • Key inventor on over 30 patents or pending patent applicatio
Slide 17: Contact us
Contact us Dr John Melki Peter Manley Genetic Signatures Genetic Signatures Chief Executive Officer Chief Financial Officer P: +61 (0)2 9870 7580 P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com E: peter.manley@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social med
Genetic Signatures — Investor Presentation (July 2020) on 6ix